Written and reviewed by Kevin Nerway · Last verified 9 August 2026
Key Takeaways
- RadNet reported second-quarter 2026 revenue of $622.7 million, a 25.0% increase from the same quarter in 2025.
- Digital Health revenue increased 56.5% to $32.4 million, while its annual recurring revenue reached $105.5 million, up 97.2% year over year.
- Adjusted EBITDA reached a quarterly record of $99.7 million, up 22.7% from the prior-year quarter.
- Adjusted EPS declined to $0.29 from $0.34 a year earlier, while first-half net loss widened to $25.9 million from $23.5 million.
RadNet Reports Record Revenue on August 9
RadNet’s RDNT earnings release on August 9, 2026 showed revenue rising 25.0% year over year to a record $622.7 million in the second quarter. The release was posted at 8:10 p.m. UTC and paired the revenue milestone with record adjusted EBITDA of $99.7 million, up 22.7% from the comparable 2025 quarter.
This is an equity-specific corporate event, not a central-bank release. The source does not provide a verified RDNT share-price reaction, broader equity-index move, FX move, or commodity-market response. I will not infer one. Traders should treat the release as a fresh fundamental catalyst for RadNet rather than evidence of a confirmed cross-market trend.
For traders tracking healthcare growth themes, the important detail is the composition of the revenue increase. RadNet’s Digital Health business expanded faster than the overall company, and the company raised full-year 2026 guidance for its Imaging Center segment. I would monitor whether subsequent trading confirms that investors are rewarding growth and guidance, or instead focusing on per-share profitability and the wider first-half loss.
For context beyond one earnings print, I would pair the release with professional-grade market research and assess whether trading volume and subsequent price acceptance support the fundamental narrative.
Digital Health Growth Drives the Earnings Narrative
Digital Health revenue reached a quarterly record of $32.4 million, a 56.5% increase from the same period last year. Annual recurring revenue for the segment reached $105.5 million as of June 30, 2026, compared with $53.5 million a year earlier, representing 97.2% growth.
That mix matters because recurring revenue can change how participants judge the durability of a company’s growth. RadNet also reported that advanced imaging procedural volumes rose 21.2%, with same-center advanced imaging volumes increasing 9.6% year over year. The combination of increased procedural activity, Digital Health expansion, and revised Imaging Center guidance is the constructive side of this release.
But the source also identifies a cost of that expansion: Digital Health adjusted EBITDA declined 27.2% from the prior year as the company invested in infrastructure. In my view, the immediate trading question is whether market participants prioritize stronger revenue and recurring-revenue growth, or demand clearer evidence that these investments will produce improved segment profitability.
Market Impact Snapshot
| Asset | Direction | Confidence |
|---|---|---|
| RDNT | Neutral | Low |
| Healthcare growth equities | Neutral | Low |
| Broad US equity market | Neutral | Low |
| US dollar | Neutral | Low |
The neutral readings reflect a reporting constraint, not a view that the results are immaterial. The source confirms RadNet’s operating data but does not document any move in RDNT, healthcare shares, equity indices, rates, or currencies. I would wait for verified market action before assigning a directional reaction.
The Profitability Tension Traders Cannot Ignore
Revenue and adjusted EBITDA both reached quarterly records, yet adjusted EPS fell to $0.29 from $0.34 in the prior-year quarter. The company also recorded a first-half 2026 net loss of $25.9 million, wider than the $23.5 million loss reported for the first half of 2025.
This creates a two-sided setup. A bullish interpretation emphasizes 25.0% company revenue growth, the 56.5% Digital Health revenue increase, a nearly doubled Digital Health annual recurring revenue figure, rising advanced-imaging volumes, and increased Imaging Center guidance. A more cautious interpretation emphasizes the lower adjusted EPS, the Digital Health EBITDA decline, and the larger first-half net loss.
That is why I would avoid assuming a one-way response from the headline numbers alone. Earnings traders should first check whether their broker or prop firm permits holding single-stock exposure around late-session company releases; however, I cannot verify any firm-specific policy from this earnings release. For funded traders who do trade equities or correlated indices, review trading restriction comparison for news traders before taking event-driven positions.
What I Would Watch After the Release
The first follow-through signal is whether market participants focus on the raised Imaging Center guidance or on the profitability measures that moved in the other direction. I would also watch future company updates for evidence that Digital Health infrastructure spending begins to translate into higher adjusted EBITDA rather than continued margin pressure.
Second, I would watch advanced imaging volumes. The 21.2% increase in advanced imaging procedural volumes and 9.6% same-center increase are central operating indicators in this report. If those trends persist, they would reinforce the company’s growth case; if they slow, the market may question the sustainability of the revenue momentum.
Third, traders considering an evaluation should separate a company-specific opportunity from an account-rule decision. Use comparing challenge rules during high-impact releases to check whether trading conditions match an earnings-focused approach, and use challenge difficulty rankings to avoid selecting an evaluation structure that is poorly suited to volatile sessions.
Practical Considerations for Funded Traders
This is not a macro release that automatically creates a defined FX or rates trade. No verified move was provided for EUR/USD, USD/JPY, gold, oil, Treasury yields, or equity indices. The actionable conclusion is therefore restraint: do not manufacture a macro trade from a corporate earnings release that has no sourced cross-asset reaction.
For traders with access to RDNT or healthcare equities, manage the event as a single-name catalyst. Confirm permitted instruments, overnight rules, and loss limits before holding exposure into the next session. A sudden repricing after earnings can make a strategy’s nominal stop distance materially different from its realized loss if liquidity changes.
I would also keep position risk small enough to remain inside account limits if the market disagrees with the initial read. Review daily loss limit policies, use prop trading calculators to model exposure, and consider whether payout comparison during active market conditions matters to your broader trading plan. Those are operational choices, but they become important when a concentrated earnings trade affects an evaluation or funded account.
Frequently Asked Questions
What did RadNet report for second-quarter 2026 revenue
RadNet reported record second-quarter revenue of $622.7 million. That was a 25.0% increase from the same quarter in 2025.
How fast did RadNet’s Digital Health segment grow
Digital Health revenue rose 56.5% year over year to $32.4 million in the second quarter. Its annual recurring revenue reached $105.5 million as of June 30, 2026, up 97.2% from $53.5 million a year earlier.
Did RadNet improve profitability in the quarter
Adjusted EBITDA increased 22.7% year over year to a record $99.7 million. However, adjusted EPS declined to $0.29 from $0.34, and Digital Health adjusted EBITDA decreased 27.2% amid infrastructure investment.
Did RadNet raise its 2026 guidance
RadNet raised its full-year 2026 Imaging Center guidance for revenue, adjusted EBITDA, and free cash flow. The company reaffirmed its expectations for the Digital Health segment.